However, clinical evidences show that treatment with a TNF-α-specific blocking antibody-CDP571 could not alleviate the symptoms of metabolic diseases (133), which may be related to the multiple sources of TNF-α from KCs (57), DCs (134), neutrophils (135), and broad effects in fatty liver disease. This evidence concerns the gene TNF and fatty liver disease.